Bienvenue sur le portail
Campus Sanofi Belgique

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?

Atopic dermatitis (AD) is a chronic inflammatory skin condition that can significantly impact patients' quality of life. Dupixent (dupilumab) has emerged as a treatment for moderate-to-severe AD. This article summarizes the findings of a 5-year open-label extension study (Beck et al, 2024), providing insights into the long-term efficacy and safety profile of Dupixent for dermatologists managing patients with persistent AD.

Felicita Andreotti, Italy; Christiaan J M Vrints, Belgium

PRALUENT^®: a powerful PCSK9i that ticks all the boxes^1–4

PRALUENT is a PCSK9i that reduces the levels of LDL-C in the blood.² It is a fully human IgG1 monoclonal antibody that works by inhibiting the binding of PCSK9 to LDL- receptors. As a result, PRALUENT increases the number of LDL-receptors available to clear LDL, thereby lowering LDL-C levels.² Elevated LDL-C levels have been significantly associated with cardiovascular disease such as heart attacks and strokes.¹

A DermTalks Podcast – Atopic Dermatitis in Special Populations. This podcast series is dedicated to exploring the management of atopic dermatitis in specific patient groups.

Speaker : Dr. Klas Agerberg, Uppsala University Hospital, Sweden

We are pleased to share this extract from our recent webinar on ‘New perspectives in the treatment of pediatrics patients with severe Atopic Dermatitis and adult patients with severe prurigo nodularis’ with you. Watch Prof. Christian Vestergaard as he offers a deep dive into Biologics and their Mode of Action pediatric AD.